oncology-ai
(3)
Leal Health
Leal Health (formerly TrialJectory) is an AI-powered treatment decision-support platform that gives cancer patients and their oncologists an unbiased, single point of access to FDA-approved therapies and clinical trials matched to a patient's exact diagnosis. Founded in 2017 and headquartered in New York, the company built a patented, generative-AI engine that reads thousands of trials and treatment options, then matches patients in a roughly two-minute intake. It has facilitated millions of treatment matches across 22+ cancer types, is free for patients and clinicians, and earns revenue from biopharma partners and health plans. In February 2026 Leal Health was acquired by Nexus Precision Health.
Triomics
Triomics builds oncology-specific AI infrastructure that turns messy, unstructured cancer patient records into structured, cited, actionable data. Its OncoLLM engine and workflow agents automate clinical trial matching, visit preparation, and cancer registry reporting for leading cancer centers, cutting manual chart review time while increasing trial enrollment. Founded in 2021 and headquartered in New York, the company is used by 4 of the top 10 U.S. cancer hospitals and raised a $22M Series B led by Battery Ventures in May 2026.
DeepScribe
DeepScribe is a San Francisco-based health-tech company building an ambient AI medical scribe that listens to natural doctor-patient conversations and turns them into complete, structured clinical notes in real time. Founded in 2017, the company has narrowed its focus to oncology, where it says it serves roughly 90% of U.S. community oncology organizations, and layers on tools for coding, pre-visit prep, and specialty-specific customization. The pitch is straightforward: let clinicians look at their patients instead of their keyboards, and cut the after-hours documentation that drives burnout.